金龙胶囊联合介入疗法治疗原发性肝癌临床观察

Kinglong capsules combined with interventional therapy for hepatocellular carcinomas:clinical observation

目的观察分别接受金龙胶囊联合肝动脉介入治疗和单纯介入疗法的原发性肝细胞癌患者的预后,比较两种方法的疗效。方法对2001年1月至2006年12月山西省肿瘤医院收治的151例肝癌患者进行随访和分析,其中74例进行介入疗法的同时加服中药金龙胶囊,77例进行单纯介入疗法,记录治疗前后生物学标志改变,并存各组指标均衡可比的基础上,采用Kappa-Menire方法比较两种治疗方法的平均生存率,中位生存期的比较采用Log-Rank检验,疗效、不良反应等资料的比较采用卡方检验。结果151例肝癌患者中位生存14个月。治疗前两组资料各指标之间差别无统计学意义(P均>0.05),组间均具可比性。金龙胶囊联合介入治疗组的中位生存期为18.5个月,单纯介入疗法组的中位生存期为11.7个月,经Log-Rank检验,两组中位生存期差别具有统计学意义(X^2=13.32,P<0.01)。两组病例疗效、生活质量变化(KPS评分)以及不良反应等的比较,差别也均有统计学意义(P均<0.05)。结论金龙胶囊联合介入治疗效果优于单纯介入化疗。

Objective To observe the prognosis of patients with primary hepatocellular carcinomas after receiving Kinglong capsules combined with interventional therapy or receiving simple interventional therapy, and to compare the therapeutic effectiveness of the two treatments. Methods A total of 151 cases with advanced hepatocellular carcinoma, who were encountered in authors＂ hospital during the period from January 2001 to December 2006, were enrolled in this study. The clinical data were retrospectively analyzed. Of the total 151 patients, 74 accepted Kinglong capsules combined with interventional therapy （study group） and 77 received simple inteIventional therapy （control group）. The survival rate was calculated by Kaplan- Meier analysis, the median survival time was estimated by Log-Rank analysis, the incidence of complications was determined by Chi-Square analysis and the AFP level in serum was evaluated by t-test. Results The median survival time for the total 151 patients was 14 months. The median survival time was 18.5 months for patients in study group, and was 11.7 months for patients in control group. Log-Rank analysis indicated that the difference in the median survival time between the two groups was statistically significant （Xz = 5.48, P 〈 0.05）. And significant differences in therapeutic effectiveness, living quality （KPS scores） and occurrence of side-effect also existed between the two groups （P 〈 0.05）. Conclusion Kinglong capsules combined with interventional therapy is superior to simple interventional therapy in treating patients with advanced hepatocellular carcinoma.